Insider trade

Officer sold ~$122K of PCVX shares in the open market

Traded Oct 1, 2026 · Filed Oct 3, 2026

~$122K
Approx. value · 2,155 sh @ $56.65: 146K
Holds after · shares reported: +19.0%
Since filing · from the first close after the filing, $56.05 → $66.70 on Oct 6, S&P 500 +2.0%

Why it stands out

Vaxcyte's Chief Scientific Ofc, COO sold $122K of Vaxcyte shares. The filing says it was made under a pre-arranged trading plan.

Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell

View the official recordSEC Form 4 — Statement of Changes in Beneficial Ownership

All the details

Officer$100K–$500KPre-arranged plan referenced

Classification

open market sale

Code S — open-market or private sale

Absolute commitment

~$122,089

Shares × reported transaction price

Timing vs results

57 days after results of Aug 5, 2026

Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results

Planned / mechanical clue

Footnote references a pre-arranged trading plan (Rule 10b5-1)

Only flagged when a footnote says so; never inferred

The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on December 9, 2025.
The price reported is a weighted-average price. The shares were sold at prices ranging from $56.065 to $56.955. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.

Planned, from payFiled 2d ago

Planned, from payFiled 2d ago

Filed 4d ago

Traded Oct 1 · filed 2 days later

Derivative exercise or conversion — not an open-market buy.